Abstract P4-08-17: First-in-human Phase 1 study of BTX-9341, a first-in-class, CDK4/6 bifunctional degrader, as a monotherapy and in combination with fulvestrant in patients with advanced and/or metastatic HR+/HER2- breast cancer
Year: 2025
Type: conference-abstract
Source: Clinical Cancer Research
Authors: Amita Patnaik, Danette Powell, Aparajita H. Chourasia, Massimo Cristofanilli, Ewelina Morawa, Jeremy Barton, Rachel M. Layman, Matthew Goetz
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4411285957